1. Home
  2. KD vs NRIX Comparison

KD vs NRIX Comparison

Compare KD & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kyndryl Holdings Inc.

KD

Kyndryl Holdings Inc.

HOLD

Current Price

$13.30

Market Cap

2.8B

Sector

Technology

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$25.33

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KD
NRIX
Founded
2020
2009
Country
United States
United States
Employees
80000
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.5B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
KD
NRIX
Price
$13.30
$25.33
Analyst Decision
Buy
Strong Buy
Analyst Count
7
12
Target Price
$25.92
$30.50
AVG Volume (30 Days)
3.6M
963.9K
Earning Date
05-06-2026
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,092,000,000.00
$76,987,000.00
Revenue This Year
$3.73
N/A
Revenue Next Year
$0.08
$48.05
P/E Ratio
N/A
N/A
Revenue Growth
0.23
99.31
52 Week Low
$10.10
$8.20
52 Week High
$33.90
$28.23

Technical Indicators

Market Signals
Indicator
KD
NRIX
Relative Strength Index (RSI) 54.44 44.71
Support Level $13.14 $14.63
Resistance Level $13.81 $24.98
Average True Range (ATR) 0.54 0.94
MACD 0.01 -0.35
Stochastic Oscillator 76.09 0.91

Price Performance

Historical Comparison
KD
NRIX

About KD Kyndryl Holdings Inc.

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Share on Social Networks: